
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix is poised for significant growth due to its promising drug pipeline, driven by the potential of Rezayato in treating fungal infections, augmented by their management's diverse and experienced expertise cultivated to achieve their goal of sustainable commercial success. The company's focus on targeting significant markets in the pharmaceutical industry also provides stability and potential for continued growth.
Bears say
Cormedix is heavily dependent on the success of DefenCath, their only commercialized product, for their future revenue growth. They have a limited product pipeline and are facing uncertainties regarding pricing and competition. Additionally, the company's recent acquisition of Melinta may add some revenue opportunities, but also brings in new risks to consider. There are concerns about the company's ability to successfully navigate post-TDAPA period and maintain profitability.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares